ACM
CATX icon

ADAR1 Capital Management’s Perspective Therapeutics CATX Stock Holding History

ADAR1 Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Buy
749,335
+654,142
+687% +$2.76M 0.18% 105
2025
Q4 		$262K Buy
+95,193
New +$272K 0.02% 216
2024
Q3 		– Sell
-69,985
Closed -$698K – 293
2024
Q2 		$698K Buy
69,985
+2,312
+3% +$33.4K 0.13% 82
2024
Q1 		$805K Buy
67,673
+63,453
+1,504% +$541K 0.18% 67
2023
Q4 		$17K Buy
+4,220
New +$11.9K 0.01% 132

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ADAR1 Capital Management's CATX Position: Q1 2026 in Review

ADAR1 Capital Management increased its Perspective Therapeutics (CATX) stake by 687% in Q1 2026, buying an estimated $2.76M and bringing the position to 749,335 shares worth $3.12M. The position accounts for 0.18% of the portfolio, ranked #105.

ADAR1 Capital Management first reported a position in CATX in Q4 2023 and has held it in 5 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • ADAR1 Capital Management held 749,335 shares of Perspective Therapeutics worth $3.12M as of Q1 2026.
  • ADAR1 Capital Management bought 654,142 Perspective Therapeutics shares in Q1 2026, an estimated $2.76M.
  • Perspective Therapeutics made up 0.18% of ADAR1 Capital Management's portfolio in Q1 2026, its #105 holding.
  • ADAR1 Capital Management first reported a position in Perspective Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.